ReviewBiomedicines2024
Irisin and Its Role in Postmenopausal Osteoporosis and Sarcopenia.
Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Potential effect of Irisin on sarcopenia: a systematic review.BMC musculoskeletal disorders · 2025Pooled it
- Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-RichNutrients · 2025Trial
- From Molecular Pathways to Artificial Intelligence: Advancing the Understanding and Management of Osteosarcopenia.International journal of molecular sciences · 2026Review
- Muscle Strength as a Key Independent Predictor of Arterial Stiffness and Metabolic Syndrome in Aging Mexicans: Unveiling the Sarcopenic Obesity Paradox.Journal of clinical medicine · 2026Article
- Protective effects of irisin in sarcopenia: a promising treatment.Journal of orthopaedic translation · 2026Review
- Musculoskeletal Assessment in Patients with Adrenal Incidentalomas: Should We Integrate the Trabecular Bone Score and/or Circulating Irisin?Diagnostics (Basel, Switzerland) · 2026Article
- Alterations in the Myokine Concentrations in Relation to Sarcopenia and Sleep Disturbances: A Narrative Review.Journal of clinical medicine · 2025Review
- X-Linked Hypophosphatemia: Role of Fibroblast Growth Factor 23 on Human Skeletal Muscle-Derived Cells.Calcified tissue international · 2025Article
- The role of irisin in exercise-induced muscle and metabolic health: a narrative review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Irisin Protects Musculoskeletal Homeostasis via a Mitochondrial Quality Control Mechanism.International journal of molecular sciences · 2024Review
- The therapeutic potential of irisin to mitigate the risk of metabolic syndrome in postmenopausal women.Frontiers in reproductive health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Menopause, an extremely delicate phase in a woman's life, is characterized by a drop in estrogen levels. This decrease has been associated with the onset of several diseases, including postmenopausal osteoporosis and sarcopenia, which often coexist in the same person, leading to an increased risk of fractures, morbidity, and mortality. To date, there are no approved pharmacological treatments for sarcopenia, while not all of those approved for postmenopausal osteoporosis are beneficial to muscles. In recent years, research has focused on the field of myokines, cytokines, or peptides secreted by skeletal muscle fibers following exercise. Among these, irisin has attracted great interest as it possesses myogenic properties but at the same time exerts anabolic effects on bone and could therefore represent the link between muscle and bone. Therefore, irisin could represent a new therapeutic strategy for the treatment of osteoporosis and also serve as a new biomarker of sarcopenia, thus facilitating diagnosis and pharmacological intervention. The purpose of this review is to provide an updated summary of what we know about the role of irisin in postmenopausal osteoporosis and sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.